Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial-Reference-Cited by-同舟云学术

Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial

Published:2021-11 Issue:11 Volume:27 Page:913.e1-913.e12
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Mehta Rohtesh S.,Bassett Roland,Chen Julianne,Valdez Benigno C.,Kawedia Jitesh,Alousi Amin M.,Anderlini Paolo,Al-Atrash Gheath,Bashir Qaiser,Ciurea Stefan O.,Hosing Chitra M.,Im Jin S.,Kebriaei Partow,Khouri Issa,Marin David,Nieto Yago,Olson Amanda,Oran Betul,Qazilbash Muzaffar H.,Ramdial Jeremy,Saini Neeraj,Srour Samer A.,Rezvani Katayoun,Shpall Elizabeth J.,Andersson Borje S.,Champlin Richard E.,Popat Uday R.

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference38 articles.

1. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes;Scott;J Clin Oncol,2017

2. Comparison of conditioning with fludarabine/busulfan and fludarabine/melphalan in allogeneic transplantation recipients 50 years or older;Kawamura;Biol Blood Marrow Transplant,2017

3. A comparison of the myeloablative conditioning regimen fludarabine/busulfan with cyclophosphamide/total body irradiation, for allogeneic stem cell transplantation in the modern era: a cohort analysis;Gooptu;Biol Blood Marrow Transplant,2018

4. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial;Popat;Lancet Haematol,2018

5. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia;Zeidner;Haematologica,2015

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Busulfan and subsequent malignancy: An evidence‐based risk assessment;Pediatric Blood & Cancer;2023-10-19

2. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities;Blood Advances;2023-10-13

3. Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial;Journal of Clinical Oncology;2023-10-10

4. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation;American Journal of Hematology;2023-06-19

5. A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study;Haematologica;2022-06-30